Frazier Life Sciences Acquisition II Closes $75 Million IPO, Adds $25 Million Forward Purchase Backstop

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Frazier Life Sciences Acquisition II completed a $75 million IPO of 7.5 million Class A shares at $10.00 per share and executed a suite of related agreements to support its SPAC strategy. The company signed an Underwriting Agreement with Jefferies, established a trust account to safeguard proceeds, granted registration rights to its sponsor and insiders, and raised $3 million via a concurrent private placement. It also secured a $25 million minimum forward purchase commitment to bolster funding at the time of its initial business combination, and put in place indemnification and governance agreements with directors, officers, and the sponsor.

Agreement 1: Frazier Life Sciences Acquisition II Closes $75 Million IPO and Enters Underwriting Agreement With Jefferies

  • Agreement type: Underwriting Agreement for IPO
  • Counterparty: Jefferies and other underwriters
  • Signed / Effective: Oct 13 2026 / Oct 13 2026
  • Duration / Termination: N/A
  • Reason: Execute and close the IPO

Agreement 2: Frazier Life Sciences Acquisition II Establishes IPO Trust Account With Continental Stock Transfer & Trust

  • Agreement type: Investment Management Trust Agreement
  • Counterparty: Continental Stock Transfer & Trust
  • Signed / Effective: Oct 13 2026 / Oct 13 2026
  • Duration / Termination: Until business combination or liquidation
  • Reason: Protect IPO proceeds pending a business combination

Agreement 3: Frazier Life Sciences Acquisition II Grants Registration Rights to Sponsor and Insiders

  • Agreement type: Registration Rights Agreement
  • Counterparty: Frazier Life Sciences Holdings II and certain officers and directors
  • Signed / Effective: Oct 13 2026 / Oct 13 2026
  • Duration / Termination: At will
  • Reason: Provide liquidity avenues for sponsor and insiders

Agreement 4: Frazier Life Sciences Acquisition II Raises $3 Million Via Private Placement With Sponsor

  • Agreement type: Private Placement Shares Purchase Agreement
  • Counterparty: Frazier Life Sciences Holdings II
  • Signed / Effective: Oct 13 2026 / Oct 13 2026
  • Duration / Termination: N/A
  • Reason: Supplement IPO proceeds and align sponsor incentives

Agreement 5: Frazier Life Sciences Acquisition II Secures $25 Million Minimum Forward Purchase Commitment

  • Agreement type: Forward Purchase Agreement (equity commitment)
  • Counterparty: Frazier Life Sciences Public Fund
  • Signed / Effective: Oct 13 2026 / Oct 13 2026
  • Duration / Termination: Until business combination closing
  • Reason: Enhance funding certainty for business combination

Agreement 6: Frazier Life Sciences Acquisition II Enters Indemnification Agreements With Directors and Officers

  • Agreement type: Indemnification Agreements for directors and officers
  • Counterparty: Company directors and officers
  • Signed / Effective: Oct 13 2026 / Oct 13 2026
  • Duration / Termination: At will
  • Reason: Support governance and attract qualified leadership

Agreement 7: Frazier Life Sciences Acquisition II Signs Sponsor and Insider Letter on Voting and Transfer Restrictions

  • Agreement type: Sponsor and Insider Letter Agreement
  • Counterparty: Frazier Life Sciences Holdings II and company directors and officers
  • Signed / Effective: Oct 13 2026 / Oct 13 2026
  • Duration / Termination: Until business combination or liquidation
  • Reason: Align incentives and govern pre-combination conduct

Original SEC Filing: Frazier Life Sciences Acquisition Corp. II [ FLSC ] - 8-K - Oct. 15, 2026

Disclaimer
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

Source: TradingView The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.